Allied-Bristol Life Sciences: CATALYST
Allied-Bristol Life Sciences (ABLS) is a joint venture of global pharmaceutical company Bristol-Myers Squibb and venture builder Allied Minds. Together, they have launched CATALYST, a new program designed to identify and develop commercially-promising biopharmaceutical innovations from leading universities and research institutions. Through CATALYST, ALBLS aims to:
- Identify therapeutic opportunities with strong translational potential and that are aligned with ABLS’s strategic areas of interest.
- License and develop lead compounds, investing ~$12M to $16M per program to undertake pre-clinical development and position the program for further clinical development and commercialization by BMS.
- Strengthen relationships with leading academic institutions.
The Principal Investigator of a CATALYST proposal must be available to collaborate with ABLS in the translation of their discovery. Strategic areas of interest include: Immuno-oncology, genetically-defined diseases, oncology, fibrosis, immunoscience, cardiovascular. Detailed information for each area of interest is in the application guidelines (link below). The information contained in the proposal is NOT deemed confidential unless the sponsoring institution has entered into a Confidentiality Agreement with ABLS that covers the proposal’s subject matter. Please consult with the technology transfer office for guidance on disclosure of confidential information.
Application Deadline: Rolling. Proposals submitted on the 1st of each month are reviewed on or before the 28th of the same month. Application Guidelines for the award: http://www.ablifescience.com/images/ABLS_Catalyst_RFP_14Jun2016.pdf.
If you have any questions about this funding opportunity, please contact Joon Cho, Industry Relations Officer, at email@example.com or (919) 843-3315. The UNC Office of Corporate and Foundation Relations is available to provide assistance in pursuing privately funded opportunities.